Whole Exome Sequencing Market Analysis

  • Report ID: 4794
  • Published Date: Sep 10, 2025
  • Report Format: PDF, PPT

Whole Exome Sequencing Market Segmentation:

Application Segment Analysis

The global whole exome sequencing market is segmented and analyzed for demand and supply by application into diagnostics, drug discovery & development, personalized medicine, and agriculture & animal research. Out of which, the personalized medicine segment is anticipated to garner the highest revenue by the end of 2035. The growth of the segment can be attributed to growing prevalence of multiple cancer forms. Since, more people than ever before are receiving their initial cancer diagnosis later in life, second cancers are becoming more prevalent. One in about five individuals with a cancer diagnosis have already experienced another type of malignancy in America. Hence, a greater focus is being placed on personalized medicine. Moreover, this is also driven by a fundamental change from the "one size fits all" model for treating individuals with disorders or a propensity for diseases, and towards one that embraces novel approaches, including personalized target medicines, to get the greatest results. In order to profit from personalized treatment, a number of national and international genome initiatives have been launched. In contrast to whole genome sequencing, exome and targeted sequencing offer a compromise between cost and utility.

Product Segment Analysis

The global whole exome sequencing market is also segmented and analyzed for demand and supply by product into systems, kits, and services. Amongst which, services segment is anticipated to have a significant growth over the forecast period. Researchers could devote more time to their work rather than tedious analytical tasks as a result of the sophisticated bioinformatics visualization capabilities given by Next-Generation Sequencing (NGS) and data analysis services. These sequence analysis services provide a variety of services, including experimental planning, library construction from a variety of samples, and downstream DNA sequence analysis. The complexity of a number of bioinformatics-related problems has been reduced for scientists and researchers owing to these services, which have also decreased the amount of time and money required for sequencing and data management. Using whole exome sequencing, which focuses on the most crucial portion of the genome, enables researchers to more effectively utilize sequencing and analytical resources.

Our in-depth analysis of the global whole exome sequencing market includes the following segments:

 

         By Product

  • Systems
  • Kits
  • Services

 

        By Technology

  • Sequencing by Synthesis
  • ION Semiconductor Sequencing

 

 

       By Application

  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Agriculture & Animal Research

 

 

        By End-User

 

  • Hospitals
  • Clinics
  • Research Centers
  • Academia & Government Institutes
  • Pharmaceutical & Biotechnology Companies 

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of whole exome sequencing is estimated at USD 3.12 billion.

The global whole exome sequencing market size was more than USD 2.66 billion in 2025 and is anticipated to witness a CAGR of more than 19.4%, crossing USD 15.66 billion revenue by 2035.

North America whole exome sequencing market will dominate more than 50.2% share by 2035, attributed to the rising prevalence of hereditary and chronic diseases and growing demand for targeted precision medicine.

Key players in the market include Illumina, Inc., Bio-Rad Laboratories Inc., Ambry Genetics, Eurofins Discovery, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., BGI Group, Macrogen Inc., Azenta US Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos